title: [Glucose effectiveness and components of the metabolic syndrome in recently diagnosed hypertensive patients].
abstract: BACKGROUND
  Glucose effectiveness (SG) is a parameter that indicates the glucose ability to clearing itself from the plasma independently of insulin's action. Our purpose was to analyze the cluster characteristics associated with the metabolic syndrome in a group of non-obese, recent-onset hypertensives and to test if there was a correlation with SG and the effectiveness of glucose at basal insulin point (GEZI).
  
  
  METHODS
  We studied 36 patients with mild hypertension with normal basal glucose levels. We determined plasma lipid subfractions, apolipoproteins and urate levels. An intravenous glucose tolerance test (TTGI) and minimal model analysis according to Bergman was performed and SG, GEZI and insulin sensitivity (SI) were calculated.
  
  
  RESULTS
  Patients with lower SG and GEZI had higher levels of total triglycerides (Tg) (r = 0.42; p = 0.01 and r = 0.48; p = 0.002, respectively) and triglycerides bind to VLDL (Tg-VLDL) (r = 0.40; p < 0.01 and r = 0.49; p = 0.002, respectively). When the cluster of metabolic syndrome was analyzed, SG was inversely related to uric acid levels and to the waist-hip index. However, SI was only related to the uric acid levels (r = 0.38; p = 0.01).
  
  
  CONCLUSIONS
  In non-obese, recently diagnosed hypertensive patients, the SG parameter seems to be an early marker for the development of metabolic syndrome.
authors.affiliation: Unidad de Hipertensión Arterial y Lípidos. Servicio de Medicina Interna. Hospitales Universitarios Virgen del Rocío. Sevilla. España. salvaymar@navegalia.com
authors.forename: José Salvador
authors.initials: JS
authors.lastname: García Morillo
authors.forename: Pablo Stiefel
authors.initials: PS
authors.lastname: García-Junco
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Miranda Guisado
authors.forename: Ignacio
authors.initials: I
authors.lastname: Vallejo Maroto
authors.forename: Encarnación
authors.initials: E
authors.lastname: Pamies Andreu
authors.forename: Ovidio
authors.initials: O
authors.lastname: Muñiz Grigalvo
authors.forename: Joaquín
authors.initials: J
authors.lastname: Carneado de la Fuente
authors.forename: José
authors.initials: J
authors.lastname: Villar Ortiz
mesh_terms: D000328:Adult; D000368:Aged; D015243:Cholesterol, VLDL / Q000097:blood; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D018149:Glucose Intolerance / Q000378:metabolism; D005951:Glucose Tolerance Test / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D049528:Insulin, Long-Acting; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D010641:Phenotype; D011863:Radioimmunoassay; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
chemical_list: D015243:Cholesterol, VLDL; D007328:Insulin; D049528:Insulin, Long-Acting; D014280:Triglycerides; D014527:Uric Acid; D005947:Glucose